Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) will showcase new real-world TMS data at the 2026 Clinical TMS Society (CTMSS) Annual Meeting as a Silver Sponsor. Presentations use the proprietary TrakStar database to examine NeuroStar TMS effectiveness across age, sex, adolescents, and maintenance therapy.
Neuronetics will also join the CTMSS PULSES Course to demonstrate NeuroStar navigation capabilities enabled by its partnership with ANT Neuro.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: BWAY and CVRX down around mid-single digits, ELMD and TLSI up mid‑single digits. Momentum scanner notes 2 peers up and 2 down (median move -4.4%), indicating broader sector dynamics rather than a purely idiosyncratic move for STIM.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Technology partnership | Positive | -13.9% | Announced strategic collaboration with ANT Neuro to integrate neuronavigation. |
| May 05 | Earnings results | Positive | +7.4% | Reported Q1 2026 revenue growth, margin details, and reiterated 2026 guidance. |
| Apr 29 | Equity inducement grants | Neutral | +14.1% | Announced 122,400 RSUs to new employees under inducement plan. |
| Apr 21 | Earnings announcement date | Neutral | -5.1% | Set date and time to release Q1 2026 results and host call. |
| Apr 13 | Coverage expansion | Positive | +3.0% | Optum/UHC policy expanded NeuroStar TMS access via PMHNPs across 26 states. |
Price has often reacted strongly to news, with mostly aligned moves except for a sharp selloff on a positive partnership announcement.
Over the last few months, Neuronetics reported expanding TMS coverage to 34.8 million covered lives, scheduled and then released Q1 2026 results, granted equity inducement awards, and announced a navigation partnership with ANT Neuro. Positive fundamental updates, such as revenue growth and coverage expansion, largely saw supportive price moves, while the ANT Neuro collaboration sold off. Today’s CTMSS research-focused announcement fits the pattern of ongoing clinical and commercial positioning for NeuroStar TMS.
Regulatory & Risk Context
An effective S-3 shelf dated March 17, 2026 registers up to 20,737,061 shares of common stock for resale by selling stockholders. The company receives no proceeds from these sales, and concentrated selling activity by these holders could affect the market price.
Market Pulse Summary
This announcement centers on Neuronetics’ CTMSS 2026 participation, showcasing real‑world TMS data, adolescent outcomes, and maintenance therapy insights, reinforcing NeuroStar’s role in evidence‑based depression care. Recent history includes coverage expansion, Q1 2026 growth, and a neuronavigation partnership, suggesting a mix of clinical and commercial milestones. Investors may watch how new data from the TrakStar database are received, alongside ongoing governance, insider activity, and the existing resale shelf registered in March 2026.
Key Terms
transcranial magnetic stimulation medical
tms medical
major depressive disorder medical
plenary technical
AI-generated analysis. Not financial advice.
New findings from the industry’s largest real-world TMS database reinforce NeuroStar’s leadership in advancing evidence-based mental health care
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting, where real-world data from the Company’s proprietary TrakStar database will be featured in an oral presentation and multiple scientific posters focused on advancing the understanding of transcranial magnetic stimulation (TMS) for mental health conditions.
NeuroStar-related presentations at CTMSS reflect the Company’s commitment to advancing TMS research and learning from real-world evidence. The Company continues to explore treatment outcomes across diverse patient populations in real-world clinical settings.
“The continued expansion of real-world evidence is critical to advancing our understanding of TMS and its role in clinical practice,” said Cory Anderson, Chief Technology Officer at Neuronetics. “These findings reflect the value of combining the industry’s largest real-world TMS database with rigorous scientific analysis to generate meaningful insights that can be shared with the broader mental health community during CTMSS.”
The following data will be presented:
The Effectiveness of Transcranial Magnetic Stimulation for Major Depressive Disorder: Associations with Age and Biological Sex
- Poster Presentation
- Presentation Date: Friday, June 5th at 4:25 - 5:55 PM ET
Real-World Antidepressant Outcomes of Transcranial Magnetic Stimulation in Adolescents Aged 12–14
- Poster Presentation
- Presentation Date: Friday, June 5th at 4:25 - 5:55 PM ET
Keeping Our Patients Better with TMS Maintenance Therapy
- Plenary VI Presentation
- Presenter: Linda Carpenter, FCTMSS, MD
- Presentation Date: Saturday, June 6th at 10:10 – 10:55 AM ET
In addition to its scientific presentations, Neuronetics will participate in the PULSES Course, a hands-on training program at CTMSS, to demonstrate NeuroStar’s navigation capabilities enabled through the Company’s partnership with ANT Neuro.
Neuronetics’ participation at CTMSS underscores the Company’s broader commitment to innovation, scientific leadership, and advancing evidence-based treatment options for patients living with depression and other mental health disorders.
For more information about NeuroStar TMS Therapy, please visit NeuroStar.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
